Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 97

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 97
---
 increase or decrease of 100,000     
 in the number of Ordinary Shares we are offering would increase or decrease, respectively, the amount of cash, cash equivalents and short-term 
 deposits, total shareholders’ (deficiency) equity and total capitalization by $1.07 million, assuming the assumed initial public               
 offering price per Ordinary Shares, as set forth on the cover page of this prospectus, remains the same. The pro forma as adjusted information 
 is illustrative only, and we will adjust this information based on the actual initial public offering price and other terms of this offering   
 determined at pricing.                                                                                                                         |

<div align='center'>59</div>

The number of the Ordinary
Shares to be issued and outstanding immediately after this offering as shown above assumes that all of the Ordinary Shares offered hereby
are sold, and is based on 3,929,378 Ordinary Shares issued and outstanding as of June 30, 2024. After giving prospective effect to
a 2.5:1 Split of our Ordinary Shares, this number excludes:

| ● | 167,365 Ordinary Shares issuable upon the exercise of warrants currently outstanding, 
 at an exercise price of $15.20;                                                       |

| ● | 79,290 Ordinary Shares issuable upon the exercise of options to consultants under                                                  
 our incentive option plan outstanding as of such date, at an exercise price of $3.97, of which 79,290 were vested as of such date; |

| ● | 485,245 Ordinary Shares issuable upon the exercise of options to chairman of the                                                            
 board of directors to be issued upon the completion of this offering under our incentive option plan (subject to anti-dilution protection), 
 at an exercise price of NIS 0.004;                                                                                                          |

| ● | 200,888 Ordinary Shares issuable upon the exercise of options to consultants and                                                 
 certain investors to be issued upon the completion of this offering under our incentive option plan, at an exercise price of NIS 
 0.004;                                                                                                                           |

| ● | Ordinary Shares underlying warrants issuable to Bridge Loan (as defined below) lenders to purchase such number of Ordinary Shares equal to two times the respective loan amount of each Bridge Loan lender, based on a price per share equal to 75% of the lowest price per share of the Company’ Ordinary Shares during the first five trading days following the consummation of this offering; |

| ● | Ordinary Shares underlying warrants issuable to 2024 Loan Ag